NCT06980142View on ClinicalTrials.gov

A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

March 17, 2028

Study Completion Date

March 17, 2028

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BIOLOGICAL

CM512

Administered SC

DRUG

Placebo

Administered SC

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06980142 - A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter